Overexpression of CCL20 and its receptor CCR6 predicts poor clinical prognosis in human gliomas
| Autor: | Jingyu Zhang, Zhenwei Zhao, Fuqiang Feng, Yongsheng Zhang, Liang Wang, Huai-zhou Qin, Guodong Gao, Ji Peigang, Gang Li, Lihong Li, Yanyang Tu |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Receptors CCR6 Cancer Research medicine.medical_specialty Pathology Adolescent chemical and pharmacologic phenomena C-C chemokine receptor type 6 Biology medicine.disease_cause Young Adult Glioma Internal medicine Biomarkers Tumor medicine Humans Child Aged Univariate analysis Chemokine CCL20 Hematology Brain Neoplasms hemic and immune systems General Medicine Middle Aged respiratory system Prognosis medicine.disease Immunohistochemistry Up-Regulation CCL20 Oncology Tumor progression Cancer research Female Neoplasm Grading Carcinogenesis |
| Zdroj: | Medical Oncology. 29:3491-3497 |
| ISSN: | 1559-131X 1357-0560 |
| DOI: | 10.1007/s12032-012-0314-9 |
| Popis: | Recent studies have demonstrated that the chemokine CCL20 and its receptor CCR6 may be involved in tumorigenesis, tumor progression and metastatic spread of various human malignancies. The aim of this study was to investigate the clinicopathological significance and prognostic value of CCL20 and CCR6 expression in human malignant glioma. CCL20 and CCR6 expression in human gliomas and nonneoplastic brain tissues was measured by immunohistochemistry. The association of CCL20 and CCR6 expression with clinicopathological factors or prognosis in glioma patients was statistically analyzed. The expression levels of CCL20 and CCR6 proteins were both up-regulated in glioma tissues. There was a significantly positive correlation between the expression of the two markers (r = 0.88; P < 0.001). In addition, the overexpressions of CCL20 and CCR6 were both detected in high-grade glioma tissues compared with those in low-grade tissues and increased with ascending tumor World Health Organization (WHO) grades (P = 0.006 and 0.008, respectively). The increased expressions of CCL20 and CCR6 proteins were also significantly correlated with low Karnofsky performance score (both P = 0.01). Moreover, univariate analysis found that CCL20 expression (P = 0.002), CCR6 expression (P = 0.002) and CCL20/CCR6 co-expression (P < 0.001) were all significantly associated with poor prognosis. In particular, glioma patients with CCL20/CCR6 co-expression have the shortest overall survival. Multivariate analysis further identified the expression levels of CCL20 and CCR6 to be independent prognostic factors. Our data suggest for the first time that CCL20 and CCR6 might play an important role in the regulation of aggressiveness in human gliomas. The up-regulation of CCL20 and CCR6 might be closely associated with poor clinical outcome of patients with gliomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink